Mirador Capital Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Mirador Capital Partners’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.49M	Buy	1,080,288 +7,052	+0.7%	+$26.8K	0.55%	45
2026 Q1	$3.77M	Buy	1,073,236 +38,692	+4%	+$124K	0.53%	45
2025 Q4	$2.82M	Buy	1,034,544 +519,519	+101%	+$1.2M	0.39%	58
2025 Q3	$1.12M	Buy	+515,025	New	+$1.22M	0.16%	95
2022 Q4	–	Sell	-63,479	Closed	-$608K	–	195
2022 Q3	$608K	Sell	63,479 -1,211	-2%	-$14K	0.15%	93
2022 Q2	$714K	Buy	64,690 +21,585	+50%	+$283K	0.17%	93
2022 Q1	$718K	Buy	43,105 +3,039	+8%	+$47K	0.15%	103
2021 Q4	$765K	Buy	40,066 +14,772	+58%	+$325K	0.16%	104
2021 Q3	$624K	Buy	25,294 +1,036	+4%	+$24.4K	0.14%	120
2021 Q2	$631K	Buy	+24,258	New	+$631K	0.14%	119

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Mirador Capital Partners's IOVA Position: Q2 2026 in Review

Mirador Capital Partners increased its Iovance Biotherapeutics (IOVA) stake by 0.66% in Q2 2026, buying an estimated $26.8K and bringing the position to 1,080,288 shares worth $4.49M. The position accounts for 0.55% of the portfolio, ranked #45.

Mirador Capital Partners first reported a position in IOVA in Q2 2021 and has held it in 10 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Mirador Capital Partners held 1,080,288 shares of Iovance Biotherapeutics worth $4.49M as of Q2 2026.
Mirador Capital Partners bought 7,052 Iovance Biotherapeutics shares in Q2 2026, an estimated $26.8K.
Iovance Biotherapeutics made up 0.55% of Mirador Capital Partners's portfolio in Q2 2026, its #45 holding.
Mirador Capital Partners first reported a position in Iovance Biotherapeutics in Q2 2021 and has held it in 10 quarters since.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Mirador Capital Partners's 13F filing for Q2 2026, filed 7 Jul 2026.